EIF4A3 and metabolic dysfunction-associated steatotic liver disease: To investigate the diagnostic capacity of EIF4A3 in plasma samples, we evaluated EIF4A3 levels in patients with NAFLD, cirrhosis and HCC, as well as control individuals (Prospective‐1 cohort; Table S2).